CLINICAL TRIALS PROFILE FOR GLPG2737
✉ Email this page to a colleague
Clinical Trials for GLPG2737
| Trial ID | Title | Status | Sponsor | Phase | Summary |
|---|---|---|---|---|---|
| NCT03128606 ↗ | A Study to Assess Safety, Tolerability and Pharmacokinetics of GLPG3067 in Healthy Subjects. | Completed | Galapagos NV | Phase 1 | The study is a First-in-Human, Phase I, randomized, double-blind, placebo-controlled, single center study, evaluating single and multiple ascending oral doses of GLPG3067 and the combination of GLPG3067 and GLPG2222 and the combination of GLPG3067,GLPG2222 and GLPG2737 given for 14 days in healthy women of non-childbearing potential. The purpose of the study is to evaluate the safety and tolerability of single ascending oral doses and multiple ascending oral doses of GLPG3067 given to healthy women of non-childbearing potential compared to placebo, as well as of multiple oral doses of the combination of GLPG3067/GLPG2222 compared to matching placebo for each compound and multiple oral doses of the combination of GLPG3067/GLPG2222/GLPG2737 compared to matching placebo for each compound. |
| NCT03410979 ↗ | A Study to Assess Safety, Tolerability and Pharmacokinetics of GLPG2737 in Healthy Subjects | Completed | Galapagos NV | Phase 1 | This study is a first-in-human (FIH), Phase I, single center, randomized, double-blind, placebo-controlled, sequential group study in healthy male subjects to assess the safety, tolerability and PK of single ascending oral doses of GLPG2737 and multiple ascending oral doses of GLPG2737 administered for 14 days. |
| NCT03450720 ↗ | Pharmacokinetics of GLPG2737 in Male Subjects With Cystic Fibrosis | Completed | Galapagos NV | Phase 1 | This is a single dose, open label study in adult male subjects with cystic fibrosis to investigate the pharmacokinetics, safety and tolerability of GLPG2737. |
| NCT03474042 ↗ | GLPG2737 on Top of Orkambi in Subjects With Cystic Fibrosis | Completed | Galapagos NV | Phase 2 | This is a Phase IIa, multi-center, randomized, double-blind, placebo-controlled, parallel-group study to evaluate GLPG2737 administered orally b.i.d. for 28 days to adult male and female subjects with a confirmed diagnosis of cystic fibrosis homozygous for the F508del CFTR mutation and on stable treatment with Orkambi. |
| NCT03540524 ↗ | A Study Looking at the Safety, Tolerability and Efficacy of the Combination of the Study Drugs GLPG2451 and GLPG2222 With or Without GLPG2737 in Patients With Cystic Fibrosis. | Completed | Galapagos NV | Phase 1 | This is a Phase Ib, multi-center, open-label, nonrandomized multiple cohorts study to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of multiple doses of a combination treatment of GLPG2451 and GLPG2222, with and without GLPG2737, in adult subjects with Cystic Fibrosis. |
| NCT04578548 ↗ | A Study to Evaluate the Effects of GLPG2737 in Participants With Autosomal Dominant Polycystic Kidney Disease (ADPKD) | Recruiting | Galapagos NV | Phase 2 | This exploratory, randomized, double-blind, placebo-controlled, multicenter, proof of concept, Phase 2a study will evaluate the efficacy, safety, tolerability, and pharmacokinetics (PK) of orally administered GLPG2737, for a treatment period of 52 weeks, in participants with rapidly progressing ADPKD. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Summary |
Clinical Trial Conditions for GLPG2737
Condition Name
Clinical Trial Locations for GLPG2737
Clinical Trial Progress for GLPG2737
Clinical Trial Phase
Clinical Trial Sponsors for GLPG2737
Sponsor Name
